Anna's Deep Dives

_{Just facts, you think for yourself}

CRISPR 2.0 & Next-Gen Technologies

CRISPR has transformed gene editing. The original CRISPR/Cas9 system allowed precise DNA cuts, enabling genetic modifications. By 2023, 84 clinical trials had used CRISPR to treat genetic disorders. However, unintended mutations still occur in up to 90% of cases.

Newer tools, like base editing and prime editing, improve accuracy. Base editing changes single DNA letters without cutting the strand, achieving 60% efficiency in fetal hemoglobin editing for sickle cell disease. Prime editing allows targeted modifications without double-strand breaks, with a 52% correction efficiency in lab models.

AI is further improving precision. Machine learning optimizes guide RNAs, reducing errors. AI-assisted tools like SeekRNA relocate genetic sequences without unnecessary proteins, minimizing unintended edits. Bridge editing connects DNA strands, enabling large modifications without leaving traces.

Alternative gene-editing systems, such as TALENs and ZFNs, offer additional approaches. CRISPR-based therapies have already entered the market, with the gene-editing sector projected to reach $9.14 billion by 2030.

Agriculture is also benefiting. With global food demand rising, CRISPR has increased gene modification rates by 6.9% in rice and 42% in Arabidopsis, enhancing crop resilience. These advancements could help address food shortages and climate challenges.

Gene therapy remains expensive. Hemgenix, the most costly treatment, is priced at $3.5 million per patient. Developing gene therapies often exceeds $1 billion, limiting accessibility. Ongoing research aims to lower costs while expanding treatment options.

The Path to Curing All Genetic Diseases

Gene editing is transforming medicine by correcting DNA errors that cause genetic diseases. CRISPR has demonstrated over 80% efficiency in treating sickle cell disease. The FDA's 2023 approval of Casgevy, the first CRISPR therapy, marked a major milestone.

Gene therapy is advancing alongside gene editing. RNA-based treatments, such as mRNA and siRNA, are being used for conditions like Duchenne muscular dystrophy and spinal muscular atrophy. The FDA approved Zolgensma in 2023 for spinal muscular atrophy, a disorder affecting 10 in 100,000 newborns.

Subscribe to Premium to read the rest.